1. Home
  2. SBFG vs RCEL Comparison

SBFG vs RCEL Comparison

Compare SBFG & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SB Financial Group Inc.

SBFG

SB Financial Group Inc.

HOLD

Current Price

$21.63

Market Cap

134.8M

Sector

Finance

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$4.13

Market Cap

123.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBFG
RCEL
Founded
1983
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.8M
123.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SBFG
RCEL
Price
$21.63
$4.13
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$7.17
AVG Volume (30 Days)
9.7K
220.4K
Earning Date
01-29-2026
02-12-2026
Dividend Yield
2.94%
N/A
EPS Growth
27.54
N/A
EPS
2.19
N/A
Revenue
$64,543,000.00
$71,610,000.00
Revenue This Year
N/A
$13.41
Revenue Next Year
N/A
$19.82
P/E Ratio
$9.56
N/A
Revenue Growth
13.68
11.45
52 Week Low
$17.10
$3.22
52 Week High
$24.22
$11.25

Technical Indicators

Market Signals
Indicator
SBFG
RCEL
Relative Strength Index (RSI) 47.25 50.36
Support Level $20.91 $3.76
Resistance Level $22.55 $4.22
Average True Range (ATR) 0.72 0.27
MACD -0.12 -0.06
Stochastic Oscillator 34.53 40.95

Price Performance

Historical Comparison
SBFG
RCEL

About SBFG SB Financial Group Inc.

SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in single segment which is Banking.

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: